The Precision Peptide Company Inc. Announces Exclusive Strategic Marketing Partnership with Mixed Martial Arts Group Limited
BPC plugs into MMA’s 5 million followers in a revenue-share gamble that could body-slam needle-phobia and vault peptides into the mainstream.
The Precision Peptide Company (BPC) has signed an exclusive strategic marketing partnership with Mixed Martial Arts Group Limited (MMA). MMA owns a global combat-sports digital ecosystem with over 5 million social-media followers, 530,000 user profiles, 75,000 active students, and 800 verified gyms. BPC’s peptide products will be marketed and sold to that audience under a tiered revenue split: 50% to each party for the first 12 months, then shifting to 75% to BPC and 25% to MMA from month 13 onward. Either side can terminate with 30 days’ written notice, but BPC must continue to pay MMA its applicable profit share on referred customers for 12 months after termination. All products will be U.S.-manufactured and FDA-compliant.
This partnership is genuinely new and was not priced in. It gives BPC immediate, capital-light distribution into a large, fitness-focused, and likely needle-averse demographic — a perfect fit for the needle-free BPC-157 patch the company has been developing. No upfront cash is required; instead BPC shares revenue only when sales occur. The revenue split heavily favors BPC after year one, and the exclusive nature limits MMA from promoting competing products. However, the deal materiality is tempered by the weak termination clause: MMA can walk away with just 30 days’ notice, making the long-term staying power conditional on near-term sales results. Set against a backdrop of aggressive marketing spending (Raw Creation, Think Ink) and advancing FDA clarity, the partnership is a logical, positive step. For a micro-cap company whose stock has recently climbed above CAD$0.50, a credible route-to-market with millions of eyes is material, though not a game-changer. I rate it Material – Positive.
The Precision Peptide Company develops and commercializes peptide-based health products. Its flagship innovation is the BPC-157 transdermal patch — a needle-free, sustained-delivery alternative to injectable peptides designed to overcome needle phobia. A second product, the Immune Defense Patch (Thymosin Alpha-1), is in the pipeline. The company sells oral peptides under the Amino Innovations brand, manufactured in an approved U.S. facility. Scientific work is supported by the University of Alberta’s Drug Development and Innovation Centre.